Hypertension Diagnostics Stock EBITDA
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Hypertension Diagnostics' long-term financial health and intrinsic value.
Hypertension |
Hypertension Diagnostics Company EBITDA Analysis
Hypertension Diagnostics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Hypertension Diagnostics EBITDA | 72.29 K |
Most of Hypertension Diagnostics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hypertension Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Hypertension Diagnostics reported earnings before interest,tax, depreciation and amortization of 72.29 K. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 100.0% higher than that of the company.
Hypertension EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hypertension Diagnostics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hypertension Diagnostics could also be used in its relative valuation, which is a method of valuing Hypertension Diagnostics by comparing valuation metrics of similar companies.Hypertension Diagnostics is currently under evaluation in ebitda category among its peers.
Hypertension Fundamentals
| Return On Asset | 3.0E-4 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.0002 % | ||||
| Current Valuation | 5.26 M | ||||
| Shares Outstanding | 52.39 M | ||||
| Price To Earning | (0.03) X | ||||
| Price To Sales | 0.15 X | ||||
| Revenue | 3.79 M | ||||
| Gross Profit | 954.47 K | ||||
| EBITDA | 72.29 K | ||||
| Net Income | (125.39 K) | ||||
| Cash And Equivalents | 5.66 K | ||||
| Total Debt | 4.69 M | ||||
| Current Ratio | 0.52 X | ||||
| Book Value Per Share | (0.09) X | ||||
| Cash Flow From Operations | (389.28 K) | ||||
| Earnings Per Share | (0) X | ||||
| Beta | -0.92 | ||||
| Market Capitalization | 730.42 K | ||||
| Total Asset | 1.28 M | ||||
| Retained Earnings | (30.68 M) | ||||
| Working Capital | (857 K) | ||||
| Current Asset | 277 K | ||||
| Current Liabilities | 1.13 M | ||||
| Z Score | -31.6 | ||||
| Net Asset | 1.28 M |
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Hypertension Pink Sheet
If you are still planning to invest in Hypertension Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hypertension Diagnostics' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |